L

Leap Therapeutics
D

LPTX

0.35500
USD
-0.01
(-1.93%)
مغلق
حجم التداول
3,027
الربح لكل سهم
-1
العائد الربحي
-
P/E
-0
حجم السوق
14,711,033
أصول ذات صلة
A
ARCT
-0.060
(-0.40%)
14.920 USD
BNTX
BNTX
0.720
(0.63%)
115.290 USD
C
CRNX
0.584
(1.92%)
30.990 USD
MRNA
MRNA
0.125
(0.37%)
34.145 USD
T
TBPH
-0.072
(-0.65%)
11.050 USD
V
VERU
-0.03740
(-6.23%)
0.56250 USD
المزيد
الأخبار المقالات

العنوان: Leap Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patientswith colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.